Index Entries

Massimo Fabiani, Maria Puopolo, Cristina Morciano, Matteo Spuri, Stefania Spila Alegiani, Antonietta Filia, Fortunato D’Ancona, Martina Del Manso, Flavia Riccardo, Marco Tallon, Valeria Proietti, Chiara Sacco, Marco Massari, Roberto Da Cas, Alberto Mateo-Urdiales, Andrea Siddu, Serena Battilomo, Antonino Bella, Anna Teresa Palamara, Patrizia Popoli, Silvio Brusaferro, Giovanni Rezza, Francesca Menniti Ippolito, and Patrizio Pezzotti
February 10, 2022
BMJ (British Medical Journal)
Italian National Institute of Health

Objectives To estimate the effectiveness of mRNA vaccines against SARS-CoV-2 infection and severe covid-19 at different time after vaccination…

Results: During the epidemic phase when the delta variant was the predominant strain of the SARS-CoV-2 virus, vaccine effectiveness against SARS-CoV-2 infection significantly decreased (P<0.001) from 82% (95% confidence interval 80% to 84%) at 3-4 weeks after the second dose of vaccine to 33% (27% to 39%) at 27-30 weeks after the second dose. In the same time intervals, vaccine effectiveness against severe covid-19 also decreased (P<0.001), although to a lesser extent, from 96% (95% to 97%) to 80% (76% to 83%). High risk people (vaccine effectiveness −6%, −28% to 12%), those aged ≥80 years (11%, −15% to 31%), and those aged 60-79 years (2%, −11% to 14%) did not seem to be protected against infection at 27-30 weeks after the second dose of vaccine.”

document
breakthrough cases,mRNA